Therapeutic vaccines for malignant brain tumors

Michael P Gustafson1, Keith L Knutson2, Allan B Dietz11Division of Transfusion Medicine; 2Department of Immunology, Mayo Clinic, Rochester, MN, USAAbstract: Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiatio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael P Gustafson, Keith L Knutson, Allan B Dietz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5f65d90bae6a4a418e4c23d5691528e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f65d90bae6a4a418e4c23d5691528e6
record_format	dspace
spelling	oai:doaj.org-article:5f65d90bae6a4a418e4c23d5691528e62021-12-02T00:56:29ZTherapeutic vaccines for malignant brain tumors1177-54751177-5491https://doaj.org/article/5f65d90bae6a4a418e4c23d5691528e62008-12-01T00:00:00Zhttp://www.dovepress.com/therapeutic-vaccines-for-malignant-brain-tumors-a2705https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Michael P Gustafson1, Keith L Knutson2, Allan B Dietz11Division of Transfusion Medicine; 2Department of Immunology, Mayo Clinic, Rochester, MN, USAAbstract: Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investigative therapies including tumor vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, specifically dendritic cell (DC) based vaccines, have shown promising results. Overall, these vaccines are well tolerated with few documented side effects. In many patients receiving vaccines, tumor progression was delayed and the median overall survival of these patients was prolonged. Despite these encouraging results, several factors have limited the efficacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant therapy and current obstacles of generating highly pure and potent DC vaccines in the context of malignant glioma. Taken together, the results from earlier clinical studies justify additional clinical trials aimed at improving the efficacy of DC vaccines.Keywords: malignant glioma, glioblastoma multiforme, vaccine, immunotherapy, dendritic cells Michael P GustafsonKeith L KnutsonAllan B DietzDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 753-761 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Michael P Gustafson Keith L Knutson Allan B Dietz Therapeutic vaccines for malignant brain tumors
description	Michael P Gustafson1, Keith L Knutson2, Allan B Dietz11Division of Transfusion Medicine; 2Department of Immunology, Mayo Clinic, Rochester, MN, USAAbstract: Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investigative therapies including tumor vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, specifically dendritic cell (DC) based vaccines, have shown promising results. Overall, these vaccines are well tolerated with few documented side effects. In many patients receiving vaccines, tumor progression was delayed and the median overall survival of these patients was prolonged. Despite these encouraging results, several factors have limited the efficacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant therapy and current obstacles of generating highly pure and potent DC vaccines in the context of malignant glioma. Taken together, the results from earlier clinical studies justify additional clinical trials aimed at improving the efficacy of DC vaccines.Keywords: malignant glioma, glioblastoma multiforme, vaccine, immunotherapy, dendritic cells
format	article
author	Michael P Gustafson Keith L Knutson Allan B Dietz
author_facet	Michael P Gustafson Keith L Knutson Allan B Dietz
author_sort	Michael P Gustafson
title	Therapeutic vaccines for malignant brain tumors
title_short	Therapeutic vaccines for malignant brain tumors
title_full	Therapeutic vaccines for malignant brain tumors
title_fullStr	Therapeutic vaccines for malignant brain tumors
title_full_unstemmed	Therapeutic vaccines for malignant brain tumors
title_sort	therapeutic vaccines for malignant brain tumors
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/5f65d90bae6a4a418e4c23d5691528e6
work_keys_str_mv	AT michaelpgustafson therapeuticvaccinesformalignantbraintumors AT keithlknutson therapeuticvaccinesformalignantbraintumors AT allanbdietz therapeuticvaccinesformalignantbraintumors
_version_	1718403385524224000

Therapeutic vaccines for malignant brain tumors

Ejemplares similares